Flovent Off Market: New Generic Approval Brings Relief
Boston News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
GlaxoSmithKlines withdrawal of Flovent, a popular childrens asthma inhaler, in December 2023, caused significant issues for families and doctors. The switch to alternatives led to worsened symptoms, more school absences, and higher out-of-pocket costs for many. The companys move to avoid new federal price controls resulted in an authorized generic version that was often more expensive and not covered by insurance. However, the recent approval of a true generic version by the FDA should make treatment more affordable and accessible for millions of kids. Senator Hassan advocates for new laws to close pricing loopholes, while GlaxoSmithKline offers assistance programs to cap costs and provide free medication for eligible patients.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/1bccfe9ea4696ff3